AEON Biopharma (NASDAQ:AEON) Receives “Buy” Rating from HC Wainwright

Posted by Linda Flegge on Apr 18th, 2024

HC Wainwright restated their buy rating on shares of AEON Biopharma (NASDAQ:AEON – Free Report) in a research note published on Wednesday, Benzinga reports. They currently have a $18.00 price target on the stock. HC Wainwright also issued estimates for AEON Biopharma’s Q1 2025 earnings at ($0.29) EPS, Q2 2025 earnings at ($0.31) EPS, Q3 2025 earnings at ($0.32) EPS and Q4 2025 earnings at ($0.24) EPS.

AEON Biopharma Trading Down 1.5 %

Shares of NASDAQ:AEON opened at $6.79 on Wednesday. AEON Biopharma has a 52-week low of $3.37 and a 52-week high of $17.17. The company has a 50-day simple moving average of $10.69 and a 200 day simple moving average of $7.78.

AEON Biopharma (NASDAQ:AEON – Get Free Report) last released its quarterly earnings data on Friday, March 29th. The company reported ($0.71) EPS for the quarter. On average, equities research analysts anticipate that AEON Biopharma will post -1.54 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. Atalaya Capital Management LP bought a new position in AEON Biopharma during the 3rd quarter worth $19,827,000. Vanguard Group Inc. bought a new position in shares of AEON Biopharma in the third quarter worth $1,085,000. Formidable Asset Management LLC acquired a new position in AEON Biopharma in the third quarter valued at about $360,000. Finally, Northern Trust Corp lifted its position in AEON Biopharma by 53.4% during the fourth quarter. Northern Trust Corp now owns 49,819 shares of the company’s stock worth $359,000 after purchasing an additional 17,341 shares during the period. Institutional investors own 22.78% of the company’s stock.

About AEON Biopharma

(Get Free Report)

AEON Biopharma, Inc, a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed a Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine.